Division of Oxford Immunotec Global PLC
Latest From Immunetics Inc.
While a panel of US FDA experts agreed that pathogen reduction technology is a promising strategy for reducing blood platelet contaminations, they raised concerns about the cost of implementing the technology. The maker of the technology, Cerus, says the panel was under-briefed and distracted.
Medtech companies raised $2.4 billion in the fourth quarter, the second-strongest of the year; Q4 device M&A deals totaled $9 billion in value, led by Allergan's $2.9 billion buy of Acelity's LifeCell division. Diagnostics financings finished out the year at $721 million, an increase over the previous quarter and 2016's second-highest quarter, but diagnostics M&A activity was the lowest of the year at $87 million, with only two completed acquisitions.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2016.
October marked one of the worst deal-making months of 2016, with only ten M&A transactions being announced and completed.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Oxford Immunotec Global PLC
- Senior Management
John Yonkin, CEO
Andrew E Levin, PhD, Pres. & Scientific Dir.
- Contact Info
Phone: (617) 896-9100
27 Drydock Ave.
Boston, MA 02210
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.